Mineralocorticoid receptor and 11β-hydroxysteroid dehydrogenase type II expression in renal cell neoplasms: A tissue microarray and quantitative RT-PCR study

American Journal of Surgical Pathology

Volumn 32, Issue 6, 2008, Pages 874-883

  Yakirevich, Evgeny ^a,b   Morris, David J ^a,b   Tavares, Rosemarie ^a,b   Meitner, Patricia A ^a,b   Lechpammer, Mirna ^a,b   Noble, Lelia ^a,b   De Rodriguez, Angela F ^c,d   Gomez Sanchez, Celso E ^c,d   Wang, Li J ^a,b   Sabo, Edmond ^a,b   Delellis, Ronald A ^a,b   Resnick, Murray B ^a,b  

^a RHODE ISLAND HOSPITAL   (United States)

^b BROWN UNIVERSITY   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d UNIVERSITY OF MISSISSIPPI   (United States)

Author keywords

11b hydroxysteroid dehydrogenase type II; Chromophobe carcinoma; Mineralocorticoid receptor; Oncocytoma; Renal cell neoplasms

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE 2; MINERALOCORTICOID RECEPTOR; 11BETA HYDROXYSTEROID DEHYDROGENASE;

ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; ONCOCYTOMA; PROTEIN ANALYSIS; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TISSUE MICROARRAY; BIOSYNTHESIS; KIDNEY TUMOR; METABOLISM; MIDDLE AGED; PATHOLOGY;

11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 2; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, RENAL CELL; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; RECEPTORS, MINERALOCORTICOID; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TISSUE ARRAY ANALYSIS;

EID: 46249095816     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0b013e31815f2362     Document Type: Article

References (37)

1. Agarwal AK, Mune T, Monder C, et al. NAD(+)-dependent isoform of 11 beta-hydroxysteroid dehydrogenase. Cloning and characterization of cDNA from sheep kidney. J Biol Chem. 1994; 269:25959-25962.
2. Albiston AL, Obeyesekere VR, Smith RE, et al. Cloning and tissue distribution of the human 11 beta-hydroxysteroid dehydrogenase type 2 enzyme. Mol Cell Endocrinol. 1994;105:R11-R17.
3. Amin MB, Amin MB, Tamboli P, et al. Prognostic impact of histologic subtyping of adult renal epithelial neoplasms: an experience of 405 cases. Am J Surg Pathol. 2002;26:281-291.
4. Arriza JL, Weinberger C, Cerelli G, et al. Cloning of human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor. Science. 1987;237:268-275.
5. Boer JM, Huber WK, Sultmann H, et al. Identification and classification of differentially expressed genes in renal cell carcinoma by expression profiling on a global human 31,500-element cDNA array. Genome Res. 2001;11:1861-1870.
6. Brem AS, Bina RB, King TC, et al. Localization of 2 11beta-OH steroid dehydrogenase isoforms in aortic endothelial cells. Hypertension. 1998;31:459-462.
7. Connell JM, Davies E. The new biology of aldosterone. J Endocrinol. 2005;186:1-20.
8. Coulter CL, Smith RE, Stowasser M, et al. Expression of 11beta-hydroxysteroid dehydrogenase type 2 (11betaHSD-2) in the developing human adrenal gland and human adrenal cortical carcinoma and adenoma. Mol Cell Endocrinol. 1999;154:71-77.
9. Eble JN, Sauter G, Epstein JI, et al. World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. Lyon, France: IARC Press; 2004.
10. Edwards CR, Stewart PM, Burt D, et al. Localization of 11 beta-hydroxysteroid dehydrogenase - tissue specific protector of the mineralocorticoid receptor. Lancet. 1988;2:986-989.
11. Funder JW, Pearce PT, Smith R, et al. Mineralocorticoid action: target tissue specificity is enzyme, not receptor, mediated. Science. 1988;242:583-585.
12. Gomez-Sanchez CE, de Rodriguez AF, Romero DG, et al. Development of a panel of monoclonal antibodies against the mineralocorticoid receptor. Endocrinology. 2006;147:1343-1348.
13. Higgins JP, Shinghal R, Gill H, et al. Gene expression patterns in renal cell carcinoma assessed by complementary DNA microarray. Am J Pathol. 2003;162:925-932.
14. Hirasawa G, Sasano H, Takahashi K, et al. Colocalization of 11 beta-hydroxysteroid dehydrogenase type II and mineralocorticoid receptor in human epithelia. J Clin Endocrinol Metab. 1997;82: z3859-3863.
15. Hirasawa G, Takeyama J, Sasano H, et al. 11 beta-hydroxysteroid dehydrogenase type II and mineralocorticoid receptor in human placenta. J Clin Endocrinol Metab. 2000;85:1306-1309.
16. Huo L, Sugimura J, Tretiakova MS, et al. C-kit expression in renal oncocytomas and chromophobe renal cell carcinomas. Hum Pathol. 2005;36:262-268.
17. Kenouch S, Lombes M, Delahaye F, et al. Human skin as target for aldosterone: coexpression of mineralocorticoid receptors and 11 beta-hydroxysteroid dehydrogenase. J Clin Endocrinol Metab. 1994; 79:1334-1341.
18. Liou LS, Shi T, Duan ZH, et al. Microarray gene expression profiling and analysis in renal cell carcinoma. BMC Urol. 2004;4:9.
19. Mazal PR, Exner M, Haitel A, et al. Expression of kidney-specific cadherin distinguishes chromophobe renal cell carcinoma from renal oncocytoma. Hum Pathol. 2005;36:22-28.
20. Mazal PR, Stichenwirth M, Koller A, et al. Expression of aquaporins and PAX-2 compared to CD10 and cytokeratin 7 in renal neoplasms: a tissue microarray study. Mod Pathol. 2005;18: 535-540.
21. McGregor DK, Khurana KK, Cao C, et al. Diagnosing primary and metastatic renal cell carcinoma: the use of the monoclonal antibody 'Renal Cell Carcinoma Marker.' Am J Surg Pathol. 2001;25: 1485-1492.
22. Rafestin-Oblin ME, Roth-Meyer C, Claire M, et al. Are miner-alocorticoid receptors present in human renal adenocarcinoma? Clin Sci. 1979;57:421-425.
23. Rohan S, Tu JJ, Kao J, et al. Gene expression profiling separates chromophobe renal cell carcinoma from oncocytoma and identifies vesicular transport and cell junction proteins as differentially expressed genes. Clin Cancer Res. 2006;12:6937-6945.
24. Rozen S, Skaletsky HJ. Primer3 on the WWW for general users and for biologist programmers. In: Krawetz S, Misener S, eds. Bioinformatics Methods and Protocols: Methods in Molecular Biology. Totowa, NJ: Humana Press; 2000:365-386.
25. Sasano H, Fukushima K, Sasaki I, et al. Immunolocalization of mineralocorticoid receptor in human kidney, pancreas, salivary, mammary and sweat glands: a light and electron microscopic immunohistochemical study. J Endocrinol. 1992;132:305-310.
26. Sasano H, Frost AR, Saitoh R, et al. Localization of mineralo-corticoid receptor and 11 beta-hydroxysteroid dehydrogenase type II in human breast and its disorders. Anticancer Res. 1997;17: 2001-2007.
27. Schuetz AN, Yin-Goen Q, Amin MB, et al. Molecular classification of renal tumors by gene expression profiling. J Mol Diagn. 2005;7:206-218.
28. Shen SS, Krishna B, Chirala R, et al. Kidney-specific cadherin, a specific marker for the distal portion of the nephron and related renal neoplasms. Mod Pathol. 2005;18:933-940.
29. Skinnider BF, Folpe AL, Hennigar RA, et al. Distribution of cytokeratins and vimentin in adult renal neoplasms and normal renal tissue: potential utility of a cytokeratin antibody panel in the differential diagnosis of renal tumors. Am J Surg Pathol. 2005;29: 747-754.
30. Smith RE, Little PJ, Maguire JA, et al. Vascular localization of the 11 beta-hydroxysteroid dehydrogenase type II enzyme. Clin Exp Pharmacol Physiol. 1996;23:549-551.
31. Storkel S, Steart PV, Drenckhahn D, et al. The human chromophobe cell renal carcinoma: its probable relation to intercalated cells of the collecting duct. Virchows Arch B Cell Pathol Incl Mol Pathol. 1989;56:237-245.
32. Suzuki S, Suzuki T, Tsubochi H, et al. Expression of 11 betahydroxysteroid dehydrogenase type 2 and mineralocorticoid receptor in primary lung carcinomas. Anticancer Res. 2000;20: 323-328.
33. Takahashi K, Sasano H, Fukushima K, et al. 11 beta-hydroxyster-oid dehydrogenase type II in human colon: a new marker of fetal development and differentiation in neoplasms. Anticancer Res. 1998;18:3381-3388.
34. Takahashi M, Rhodes DR, Furge KA, et al. Gene expression profiling of clear cell renal cell carcinoma: gene identification and prognostic classification. Proc Natl Acad Sci USA. 2001;98: 9754-9759.
35. Takahashi M, Yang XJ, Sugimura J, et al. Molecular subclassifica-tion of kidney tumors and the discovery of new diagnostic markers. Oncogene. 2003;22:6810-6818.
36. Tretiakova MS, Sahoo S, Takahashi M, et al. Expression of alphamethylacyl-CoA racemase in papillary renal cell carcinoma. Am J Surg Pathol. 2004;28:69-76.
37. Young AN, Amin MB, Moreno CS, et al. Expression profiling of renal epithelial neoplasms: a method for tumor classification and discovery of diagnostic molecular markers. Am J Pathol. 2001;158: 1639-1651.